Cytomedix, Inc. Stock OTC Bulletin Board
Equities
CMXI
US23283B2043
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
05-20 | Nuo Therapeutics, Inc. announced that it has received $0.650875 million in funding | CI |
05-15 | Nuo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2022 | 112K 154K | Sales 2023 | 609K 832K | Capitalization | 24.33M 33.28M |
---|---|---|---|---|---|
Net income 2022 | -3M -4.1M | Net income 2023 | -3M -4.1M | EV / Sales 2022 | 543 x |
Net cash position 2022 | 1.72M 2.35M | Net cash position 2023 | 673K 920K | EV / Sales 2023 | 38.9 x |
P/E ratio 2022 |
-18.9
x | P/E ratio 2023 |
-7.3
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 41.75% |
Managers | Title | Age | Since |
---|---|---|---|
David Jorden
CEO | Chief Executive Officer | 61 | 08-09-18 |
Peter Clausen
COO | Chief Operating Officer | 58 | 08-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
C. Winzer
BRD | Director/Board Member | 67 | 09-01-29 |
David Jorden
CEO | Chief Executive Officer | 61 | 08-09-18 |
Paul Mintz
BRD | Director/Board Member | 75 | 17-04-06 |
1st Jan change | Capi. | |
---|---|---|
+20.17% | 126B | |
+24.67% | 118B | |
+25.44% | 27.87B | |
-17.74% | 20.95B | |
-15.17% | 16.92B | |
-15.21% | 16.18B | |
+11.91% | 14.84B | |
-47.10% | 14.79B | |
+54.50% | 14.08B |
- Stock Market
- Equities
- AURX Stock
- CMXI Stock